By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ACADIA Pharmaceuticals, Inc. 

3911 Sorrento Valley Boulevard

San Diego  California  92121   U.S.A.
Phone: 858-558-2871 Fax: 858-558-2872


ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders.


July 16, 1993


Founder: Mark Brann

CEO: Stephen Davis

CMO (Medical): Randall Owen


Please click here for Acadia Pharma job opportunities.


Please click here for clinical trial information.


All Products

Key Statistics

Ownership: Public

Web Site: Acadia
Employees: 140
Symbol: ACAD

Drug Discovery


Allergan  Discovery of alpha adrenergic drug candidates that may represent a significant breakthrough in the treatment of neuropathic pain.

Allergan  Develop and commercialize selective muscarinic drugs for the treatment of glaucoma.

Allergan  The third collaboration is designed to leverage ACADIA's R&D platform to discover and develop new therapeutics predominantly in the area of pain.

Sunovion Pharmaceuticals Inc.  ACADIA has formed a broad CNS collaboration with Sepracor for the discovery and development of new drug candidates against muscarinic receptors.

Company News
Acadia (ACAD) Announces Full Exercise Of Underwriters' Option To Purchase Additional Shares 8/24/2016 9:52:02 AM
Acadia (ACAD) Scores Former Baxalta (BXLT) Exec as New CFO 8/24/2016 7:10:00 AM
3 High-Risk, High-Reward Biotech Stocks 8/24/2016 6:15:40 AM
Acadia (ACAD) Prices Public Offering Of Common Stock 8/10/2016 9:46:15 AM
Acadia (ACAD) Announces Proposed Public Offering Of Common Stock 8/9/2016 11:16:13 AM
Acadia (ACAD) Reports Second Quarter 2016 Financial Results 8/5/2016 11:05:28 AM
Acadia (ACAD) To Announce Second Quarter 2016 Financial Results On August 4, 2016 8/1/2016 11:01:42 AM
Acadia (ACAD) To Present At The JMP Securities Life Sciences Conference On June 21, 2016 6/16/2016 10:19:44 AM
Acadia (ACAD) To Present At The Goldman, Sachs & Co. 37th Annual Global Healthcare Conference On June 8, 2016 6/1/2016 4:49:35 PM
Acadia (ACAD) Announces NUPLAZID (Pimavanserin) Is Now Available For The Treatment Of Hallucinations And Delusions Associated With Parkinson’s Disease Psychosis 5/31/2016 10:52:08 AM